RxDoctor Payments Data

Brian Goss, PA

Medical · Everett, PANPI 1952887564

Payments from drug & device makers

$4,093in general payments, 2019–2025

Across 160 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1K
  • Astellas Pharma US Inc$873
  • Teleflex LLC$712
  • Pfizer$208
  • Urovant Sciences Inc$165
  • Axonics, Inc.$144
  • plus $795 from 15 others

What the payments were for

  • Travel & lodging$66016%
  • Food & beverage$2,94472%
  • Education$48912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,093 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$107,124
Medicare patients
482
Services billed
2,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide15$211,116
MyrbetriqMirabegron169$133,113
GemtesaVibegron71$52,777
Tamsulosin Hcl759$21,805
Mirabegron ErMirabegron39$17,948
PremarinEstrogens, Conjugated37$15,724
Solifenacin Succinate272$8,550
Methenamine Hippurate37$3,422
Alfuzosin Hcl ErAlfuzosin Hcl118$3,380
Oxybutynin Chloride ErOxybutynin Chloride96$2,320
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst50$1,962
Trospium Chloride ErTrospium Chloride14$1,673
Estradiol22$1,656
Gentamicin Sulfate12$1,426
Finasteride63$1,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$873$344,229184 claims
Sumitomo Pharma America, Inc.Gemtesa$1,196$52,77771 claims
PfizerPremarin$208$15,72437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Everett

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →